U.S. Backs Roche Cervical Cancer Test
April 26, 2011
The U.S. Food and Drug Administration has approved Roche Holding AG's new cobas human papillomavirus test, which can detect several high-risk strains of HPV, the firm recently announced. FDA supported the cobas HPV Test after reviewing its use in a clinical trial involving more than 47,000 women.
"The test is fully automated, has a high reliability and throughput rate," said Daniel O'Day, head of Roche's diagnostics division.
Wall Street Journal
04.20.2011; Goran Mijuk
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)